600 related articles for article (PubMed ID: 11290435)
1. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
2. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
4. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
Twelves C; Gollins S; Grieve R; Samuel L
Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278
[TBL] [Abstract][Full Text] [Related]
5. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
6. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Van Cutsem E; Hoff PM; Harper P; Bukowski RM; Cunningham D; Dufour P; Graeven U; Lokich J; Madajewicz S; Maroun JA; Marshall JL; Mitchell EP; Perez-Manga G; Rougier P; Schmiegel W; Schoelmerich J; Sobrero A; Schilsky RL
Br J Cancer; 2004 Mar; 90(6):1190-7. PubMed ID: 15026800
[TBL] [Abstract][Full Text] [Related]
7. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Scheithauer W; McKendrick J; Begbie S; Borner M; Burns WI; Burris HA; Cassidy J; Jodrell D; Koralewski P; Levine EL; Marschner N; Maroun J; Garcia-Alfonso P; Tujakowski J; Van Hazel G; Wong A; Zaluski J; Twelves C;
Ann Oncol; 2003 Dec; 14(12):1735-43. PubMed ID: 14630678
[TBL] [Abstract][Full Text] [Related]
8. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Ward S; Kaltenthaler E; Cowan J; Brewer N
Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
[TBL] [Abstract][Full Text] [Related]
9. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Cassidy J; Twelves C; Van Cutsem E; Hoff P; Bajetta E; Boyer M; Bugat R; Burger U; Garin A; Graeven U; McKendric J; Maroun J; Marshall J; Osterwalder B; Pérez-Manga G; Rosso R; Rougier P; Schilsky RL;
Ann Oncol; 2002 Apr; 13(4):566-75. PubMed ID: 12056707
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
Di Costanzo F; Ravasio R; Sobrero A; Bertetto O; Vinante O; Luppi G; Labianca R; Amadori D; Barone C; Carlo Merlano M; Longo F; Mansueto G; Antonuzzo L; Gasperoni S
Clin Drug Investig; 2008; 28(10):645-55. PubMed ID: 18783303
[TBL] [Abstract][Full Text] [Related]
11. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Van Cutsem E; Verslype C; Tejpar S
Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
[TBL] [Abstract][Full Text] [Related]
12. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Hoff PM; Ansari R; Batist G; Cox J; Kocha W; Kuperminc M; Maroun J; Walde D; Weaver C; Harrison E; Burger HU; Osterwalder B; Wong AO; Wong R
J Clin Oncol; 2001 Apr; 19(8):2282-92. PubMed ID: 11304782
[TBL] [Abstract][Full Text] [Related]
13. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
14. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Twelves CJ
Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
[TBL] [Abstract][Full Text] [Related]
15. The evolution of fluoropyrimidine therapy: from intravenous to oral.
Hoff PM; Cassidy J; Schmoll HJ
Oncologist; 2001; 6 Suppl 4():3-11. PubMed ID: 11585968
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.
Twelves C;
Eur J Cancer; 2002 Feb; 38 Suppl 2():15-20. PubMed ID: 11841931
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.
McGavin JK; Goa KL
Drugs; 2001; 61(15):2309-26. PubMed ID: 11772141
[TBL] [Abstract][Full Text] [Related]
18. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
[TBL] [Abstract][Full Text] [Related]
19. Potential of Xeloda in colorectal cancer and other solid tumors.
Cassidy J
Oncology; 1999 Jul; 57 Suppl 1():27-32. PubMed ID: 10436414
[TBL] [Abstract][Full Text] [Related]
20. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
